FDA Approves First Non-opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889
The FDA today approved lofexidine hydrochloride (Lucemyra) for the mitigation of opioid withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults, aged 18 and older. While lofexidine hydrochloride may lessen the severity of withdrawal symptoms, it may not completely prevent them, and is only approved for treatment for up to 14 days, according to a press release issued by the FDA. Lofexidine hydrochloride is not a treatment for opioid use disorder (OUD), but can be used as part of a broader, long-term treatment plan for managing the condition.
“As part of our commitment to support patients struggling with addiction, we’re dedicated to encouraging innovative approaches to help mitigate the physiological challenges presented when patients discontinue opioids,” said FDA Commissioner Scott Gottlieb, MD, in a statement. “We’re developing new guidance to help accelerate the development of better treatments, including those that help manage opioid withdrawal symptoms.